Transfer Factor Timeline: From Lawrence 1949 to Max 2026

Transfer factor is a class of low-molecular-weight molecules, first described in 1949, that appear to carry immune recognition information from one organism to another. It was discovered by the American immunologist Dr. H. Sherwood Lawrence at New York University School of Medicine, who demonstrated that a cell-free extract of white blood cells could transfer delayed-type hypersensitivity from an immune donor to a non-immune recipient. Transfer factors have since been identified in bovine colostrum, hen egg yolk and — most recently — plant seeds, and they form the basis of the 4Life Transfer Factor® product line.

Most pages that tell this story tell half of it. They give you Lawrence in 1949 and then jump to a product, skipping both the decades of difficult science in between and the parts of the record that are genuinely contested. This is the full version — dated, sourced, and honest about where each claim comes from. Here's the version we'd want our own family to read before deciding what to make of the ingredient.

Why a timeline is the honest format

Transfer factor has an unusual profile for a supplement ingredient: a long, serious academic history and a long history of methodological argument, running in parallel. Presenting it as a list of benefits flattens both. Presenting it as a timeline lets you see what was actually established, when, by whom — and which links in the chain are strong.

So each era below carries an explicit note on the quality of the evidence behind it. Where a date comes from 4Life's own published company history rather than an independent record, we say that plainly instead of dressing it up as settled fact.

1949 — the experiment that started it

Dr. H. Sherwood Lawrence was studying tuberculin sensitivity, the delayed skin reaction that develops in people who have been exposed to tuberculosis. He took white blood cells from tuberculin-positive donors, ruptured the cells, and injected the resulting cell-free extract into tuberculin-negative recipients.

The recipients then tested positive. Their immune systems reacted to tuberculin as though they had encountered it before — but no living cells, and no antibodies of the kind then understood, had been transferred. Lawrence concluded the extract carried some transferable factor of immune recognition, and the name stuck.

That distinction matters, and it still does. Lawrence's work was about immune education — recognition and memory — not about direct antimicrobial action. Every legitimate description of transfer factor since has stayed inside that frame.

Evidence: Peer-reviewed. Lawrence, H.S. (1949), Proceedings of the Society for Experimental Biology and Medicine 71:516–522.

1950s–1980s — defining it, and arguing about it

Lawrence spent the next four decades characterizing what he had found. By the mid-1950s he had defined the active material in terms of dialyzable leukocyte extract (DLE) — the small-molecule fraction that passes through a dialysis membrane when white blood cells are lysed. He also showed the effect was not limited to tuberculin; sensitivity to streptococcal M protein transferred the same way.

He published major syntheses in the Annals of the New York Academy of Sciences, including papers in 1965 and 1970, and the field expanded into clinical immunotherapy research using DLE preparations.

It also ran into a wall that has never fully come down. DLE is a mixture. Isolating a single purified molecule responsible for the effect proved extremely difficult, preparation methods varied between laboratories, and many mid-century clinical studies were small. Reviews in the immunology literature have since gone through the claims to separate what the evidence supports from what it doesn't. That critical literature is part of the record, and reading it is part of evaluating the ingredient fairly.

Evidence: Peer-reviewed, and genuinely contested. Both the supportive and the critical literature are indexed in PubMed.

The 1980s–1990s — from donors to colostrum

A practical problem sat on top of the scientific one. Extracts from human white blood cells are not a viable consumer ingredient, at any scale or any price.

The path forward came from a piece of ordinary biology: mammals already transfer immune information to their offspring. A cow's colostrum — the dense first milk produced after calving — carries immune factors to a calf whose own immune system has not yet built a memory. Hens do something comparable, depositing immune material into the yolk of the egg.

That reframed the supply question. If transfer factors occur naturally in colostrum and yolk, the problem becomes extraction and concentration rather than donation. Patented filtration methods for isolating those fractions are what made a shelf-stable transfer factor ingredient possible at all.

Evidence: The biology of colostral immune transfer is well established and independently documented. Specific patent dates in this era are most commonly sourced to 4Life's own published history; treat them as company-sourced.

1998 — 4Life Research is founded

According to 4Life's published company history, David and Bianca Lisonbee licensed the patent covering extraction of transfer factors from cow colostrum and founded 4Life Research USA, LLC in Sandy, Utah, in 1998. The company built its product line around that ingredient and has described itself since as "The Immune System Company."

4Life's history also records a later patent covering extraction of transfer factors from hen egg yolk, which enabled the combination of colostrum-derived and egg-derived fractions in a single formula.

Evidence: Company-sourced. Founding date and Utah headquarters are independently verifiable; the licensing narrative comes from 4Life's own materials.

The Tri-Factor era — three fractions, one blend

The combination approach produced the architecture still in use today. Three proprietary fractions, from two animal sources:

Together these three make up Tri-Factor®, which supplies 600 mg of the 900 mg of 4Life Transfer Factor in each daily serving of Transfer Factor Max. If you want the direct generational comparison, we set it out in Transfer Factor Max vs Tri-Factor Formula.

Evidence: Fraction identities and the 600 mg figure are published on 4Life's product label and corporate product page. Specific launch years for each fraction are company-sourced and we don't assert them here.

2024 — a peer-reviewed activation study

In 2024, Yu, Iloba, Cruickshank and Jensen published in Current Issues in Molecular Biology (volume 46, pages 6710–6724) a study examining immune cell activation following exposure to 4Life transfer factor material, reporting measurable activation within a two-hour window.

This is the strongest recent citation in the set, for a specific reason: it is an independently peer-reviewed journal article rather than an internal document. We walk through its design and its limits in The Clinical Studies Behind Transfer Factor Max.

Evidence: Peer-reviewed journal publication.

2026 — PhytoFactor, and the first plant source

The launch of 4Life Transfer Factor Max in 2026 marks the first structural change to the ingredient's sourcing in roughly two decades: the addition of PhytoFactor™, a transfer factor fraction derived from the seeds of Brassica napus — the plant better known as rapeseed or canola.

Every earlier generation drew on animal immunity: human leukocytes, then cow colostrum, then hen egg yolk. PhytoFactor is the first plant-sourced fraction in the commercial line, contributing 300 mg to bring the daily total to 900 mg. We cover the botany in Brassica napus: The Plant Behind PhytoFactor and the mechanism question in PhytoFactor vs Animal Transfer Factor.

Two further sources are frequently cited alongside the 2026 launch — a 4Life technical white paper by Gardner and colleagues on stem cell mobilization, and an internal clinical report by Jensen and colleagues on neutrophil activation. Both are worth knowing about. Neither is an independently peer-reviewed journal article, and we'd rather tell you that than let the citation count do work the citations can't.

Evidence: Mixed. Formula composition is label-verified; Gardner 2026 and Jensen 2026 are company technical documents.

The four sources, side by side

The cleanest way to see 77 years of change is to look at what the material was extracted from, and what that made possible.

Recognize · Respond · Remember · Renew

4Life frames the whole arc in four verbs, and the framing is a fair summary of what Lawrence was actually describing. The immune system recognizes a challenge, responds to it, remembers it for next time, and renews its readiness. Transfer factors are positioned as supporting that education process.*

What it is not: a claim that the ingredient treats, cures or prevents any disease. Seventy-seven years of research have produced a real and interesting body of work on immune recognition, alongside real and unresolved methodological questions. Both halves are in this timeline because both halves are true.

Where Transfer Factor Max sits today

The current flagship delivers 900 mg of 4Life Transfer Factor per daily serving — 600 mg Tri-Factor plus 300 mg PhytoFactor — alongside the 843 mg Cordyvant™ polysaccharide complex (IP-6, a super-mushroom blend, oats and baker's yeast), plus vitamin C, high-potency vitamin D3 and zinc at 90% DV. The serving is four vegetable capsules daily with food and 8 oz of water; each 120-capsule bottle is a 30-day supply.

For the complete label breakdown, see Every Ingredient in Transfer Factor Max, Dose by Dose.

*These statements have not been evaluated by the Food and Drug Administration. Transfer Factor Max is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Consult your healthcare provider before beginning any new supplement program.